Difference between revisions of "Gestational trophoblastic neoplasia"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "{| class="wikitable" style="width: 100%" to "{| class="wikitable sortable" style="width: 100%") |
m |
||
Line 53: | Line 53: | ||
===References=== | ===References=== | ||
# Osathanondh R, Goldstein DP, Pastorfide GB. Actinomycin D as the primary agent for gestational trophoblastic disease. Cancer. 1975 Sep;36(3):863-6. [https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(197509)36:3%3C863::AID-CNCR2820360306%3E3.0.CO;2-G link to original article] [https://pubmed.ncbi.nlm.nih.gov/171055 PubMed] | # Osathanondh R, Goldstein DP, Pastorfide GB. Actinomycin D as the primary agent for gestational trophoblastic disease. Cancer. 1975 Sep;36(3):863-6. [https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(197509)36:3%3C863::AID-CNCR2820360306%3E3.0.CO;2-G link to original article] [https://pubmed.ncbi.nlm.nih.gov/171055 PubMed] | ||
− | # '''GOG 0174:''' Osborne RJ, Filiaci V, Schink JC, Mannel RS, Alvarez Secord A, Kelley JL, Provencher D, Scott Miller D, Covens AL, Lage JM. Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. J Clin Oncol. 2011 Mar 1;29(7):825-31. Epub 2011 Jan 24. [https://doi.org/10.1200/JCO.2010.30.4386 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068058/ link to PMC article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/21263100 PubMed] | + | # '''GOG 0174:''' Osborne RJ, Filiaci V, Schink JC, Mannel RS, Alvarez Secord A, Kelley JL, Provencher D, Scott Miller D, Covens AL, Lage JM. Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. J Clin Oncol. 2011 Mar 1;29(7):825-31. Epub 2011 Jan 24. [https://doi.org/10.1200/JCO.2010.30.4386 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068058/ link to PMC article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/21263100 PubMed] NCT00003702 |
==EMA-CO {{#subobject:418f07|Regimen=1}}== | ==EMA-CO {{#subobject:418f07|Regimen=1}}== | ||
Line 109: | Line 109: | ||
===Regimen {{#subobject:b3d0ec|Variant=1}}=== | ===Regimen {{#subobject:b3d0ec|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 100%; text-align:center;" | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
− | !style="width: | + | !style="width: 20%"|Study |
− | !style="width: | + | !style="width: 20%"|Years of enrollment |
− | !style="width: | + | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] |
− | !style="width: | + | !style="width: 20%"|Comparator |
+ | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
|[https://doi.org/10.3181/00379727-93-22757 Li et al. 1956] | |[https://doi.org/10.3181/00379727-93-22757 Li et al. 1956] | ||
+ | |NR | ||
| style="background-color:#ffffbe" |Pilot | | style="background-color:#ffffbe" |Pilot | ||
| style="background-color:#d3d3d3" | | | style="background-color:#d3d3d3" | | ||
Line 120: | Line 122: | ||
|- | |- | ||
|[https://doi.org/10.1056/nejm195807102590204 Li et al. 1958] | |[https://doi.org/10.1056/nejm195807102590204 Li et al. 1958] | ||
+ | |1955-1957 | ||
| style="background-color:#ffffbe" |Pilot | | style="background-color:#ffffbe" |Pilot | ||
| style="background-color:#d3d3d3" | | | style="background-color:#d3d3d3" | | ||
Line 125: | Line 128: | ||
|- | |- | ||
|[https://obgyn.onlinelibrary.wiley.com/doi/abs/10.1016/0020-7292(89)90779-0 Homesley et al. 1988] | |[https://obgyn.onlinelibrary.wiley.com/doi/abs/10.1016/0020-7292(89)90779-0 Homesley et al. 1988] | ||
+ | |NR in abstract | ||
| style="background-color:#91cf61" |Phase II | | style="background-color:#91cf61" |Phase II | ||
| style="background-color:#d3d3d3" | | | style="background-color:#d3d3d3" | | ||
Line 130: | Line 134: | ||
|- | |- | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068058/ Osborne et al. 2011 (GOG 0174)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068058/ Osborne et al. 2011 (GOG 0174)] | ||
+ | |1999-2007 | ||
|style="background-color:#1a9851"|Phase III (C) | |style="background-color:#1a9851"|Phase III (C) | ||
|[[#Dactinomycin_monotherapy|Dactinomycin]] | |[[#Dactinomycin_monotherapy|Dactinomycin]] | ||
Line 145: | Line 150: | ||
# Li MC, Hertz R, Bergenstal DM. Therapy of choriocarcinoma and related trophoblastic tumors with folic acid and purine antagonists. N Engl J Med. 1958 Jul 10;259(2):66-74. [https://doi.org/10.1056/nejm195807102590204 link to original article] [https://pubmed.ncbi.nlm.nih.gov/13566422 PubMed] | # Li MC, Hertz R, Bergenstal DM. Therapy of choriocarcinoma and related trophoblastic tumors with folic acid and purine antagonists. N Engl J Med. 1958 Jul 10;259(2):66-74. [https://doi.org/10.1056/nejm195807102590204 link to original article] [https://pubmed.ncbi.nlm.nih.gov/13566422 PubMed] | ||
# Homesley HD, Blessing JA, Rettenmaier M, Capizzi RL, Major FJ, Twiggs LB. Weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease. Obstet Gynecol. 1988 Sep;72(3 Pt 1):413-8. [https://obgyn.onlinelibrary.wiley.com/doi/abs/10.1016/0020-7292(89)90779-0 link to original article] [https://pubmed.ncbi.nlm.nih.gov/2457192 PubMed] | # Homesley HD, Blessing JA, Rettenmaier M, Capizzi RL, Major FJ, Twiggs LB. Weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease. Obstet Gynecol. 1988 Sep;72(3 Pt 1):413-8. [https://obgyn.onlinelibrary.wiley.com/doi/abs/10.1016/0020-7292(89)90779-0 link to original article] [https://pubmed.ncbi.nlm.nih.gov/2457192 PubMed] | ||
− | # '''GOG 0174:''' Osborne RJ, Filiaci V, Schink JC, Mannel RS, Alvarez Secord A, Kelley JL, Provencher D, Scott Miller D, Covens AL, Lage JM. Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. J Clin Oncol. 2011 Mar 1;29(7):825-31. Epub 2011 Jan 24. [https://doi.org/10.1200/JCO.2010.30.4386 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068058/ link to PMC article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/21263100 PubMed] | + | # '''GOG 0174:''' Osborne RJ, Filiaci V, Schink JC, Mannel RS, Alvarez Secord A, Kelley JL, Provencher D, Scott Miller D, Covens AL, Lage JM. Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. J Clin Oncol. 2011 Mar 1;29(7):825-31. Epub 2011 Jan 24. [https://doi.org/10.1200/JCO.2010.30.4386 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068058/ link to PMC article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/21263100 PubMed] NCT00003702 |
[[Category:Gestational trophoblastic neoplasia regimens]] | [[Category:Gestational trophoblastic neoplasia regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Gynecologic cancers]] | [[Category:Gynecologic cancers]] |
Revision as of 17:23, 10 October 2020
Section editor | |
---|---|
Summer B. Dewdney, MD Rush University Chicago, IL |
4 regimens on this page
6 variants on this page
|
Guidelines
ESMO
- 2013: Seckl et al. Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
NCCN
Low-risk disease, all lines of therapy
Dactinomycin monotherapy
back to top |
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Osathanondh et al. 1975 | 1965-1973 | Non-randomized (RT) | ||
Osborne et al. 2011 (GOG 0174) | 1999-2007 | Phase III (E-switch-ic) | Methotrexate | Seems to have superior CR rate |
Chemotherapy
- Dactinomycin (Cosmegen) 1.25 mg/m2 IV push once on day 1
14-day cycles "until the βhCG assay had reached the institutional normal, or until either a rise or plateau in the βhCG level was observed"
References
- Osathanondh R, Goldstein DP, Pastorfide GB. Actinomycin D as the primary agent for gestational trophoblastic disease. Cancer. 1975 Sep;36(3):863-6. link to original article PubMed
- GOG 0174: Osborne RJ, Filiaci V, Schink JC, Mannel RS, Alvarez Secord A, Kelley JL, Provencher D, Scott Miller D, Covens AL, Lage JM. Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. J Clin Oncol. 2011 Mar 1;29(7):825-31. Epub 2011 Jan 24. link to original article link to PMC article contains verified protocol PubMed NCT00003702
EMA-CO
back to top |
EMA-CO: Etoposide, Methotrexate, Actinomycin D, Cyclophosphamide, Oncovin (Vincristine)
Regimen
Study | Years of enrollment | Evidence |
---|---|---|
Newlands et al. 1991 | 1979-1989 | Non-randomized (RT) |
Chemotherapy
- Etoposide (Vepesid)
- Methotrexate (MTX)
- Dactinomycin (Cosmegen)
- Cyclophosphamide (Cytoxan)
- Vincristine (Oncovin)
References
- Newlands ES, Bagshawe KD, Begent RH, Rustin GJ, Holden L. Results with the EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) regimen in high risk gestational trophoblastic tumours, 1979 to 1989. Br J Obstet Gynaecol. 1991 Jun;98(6):550-7. link to original article PubMed
Mercaptopurine & Methotrexate
back to top |
Regimen
Study | Evidence |
---|---|
Li et al. 1958 | Pilot |
Note: this is of historic interest.
Chemotherapy
References
- Li MC, Hertz R, Bergenstal DM. Therapy of choriocarcinoma and related trophoblastic tumors with folic acid and purine antagonists. N Engl J Med. 1958 Jul 10;259(2):66-74. link to original article PubMed
Methotrexate monotherapy
back to top |
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Li et al. 1956 | NR | Pilot | ||
Li et al. 1958 | 1955-1957 | Pilot | ||
Homesley et al. 1988 | NR in abstract | Phase II | ||
Osborne et al. 2011 (GOG 0174) | 1999-2007 | Phase III (C) | Dactinomycin | Seems to have inferior CR rate |
Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.
Chemotherapy
- Methotrexate (MTX) 30 mg/m2 IM once on day 1
7-day cycles "until the βhCG assay had reached the institutional normal, or until either a rise or plateau in the βhCG level was observed"
References
- Li MC, Hertz R, Spencer DB. Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma. Proc Soc Exp Biol Med. 1956 Nov;93(2):361-6. link to original article PubMed
- Li MC, Hertz R, Bergenstal DM. Therapy of choriocarcinoma and related trophoblastic tumors with folic acid and purine antagonists. N Engl J Med. 1958 Jul 10;259(2):66-74. link to original article PubMed
- Homesley HD, Blessing JA, Rettenmaier M, Capizzi RL, Major FJ, Twiggs LB. Weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease. Obstet Gynecol. 1988 Sep;72(3 Pt 1):413-8. link to original article PubMed
- GOG 0174: Osborne RJ, Filiaci V, Schink JC, Mannel RS, Alvarez Secord A, Kelley JL, Provencher D, Scott Miller D, Covens AL, Lage JM. Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. J Clin Oncol. 2011 Mar 1;29(7):825-31. Epub 2011 Jan 24. link to original article link to PMC article contains verified protocol PubMed NCT00003702